Chemomab Therapeutics Ltd. (CMMB)
Nasdaq · Healthcare · Biotechnology
$1.41−1.40%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $10.3M
- 52-week range
- $1.05 – $3.58
- 52-week change
- −50.17%
- EPS (trailing)
- −$1.04
Fiscal year to Dec 2025
- Net income
- −$9.0M
- Diluted EPS
- $0.018
- Free cash flow
- −$11.1M
From the company’s annual report on SEC EDGAR.
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Headquarters: Tel Aviv-Yafo, Israel · chemomab.com